NASDAQ:FENC

Fennec Pharmaceuticals Stock Forecast, Price & News

$6.80
-0.17 (-2.44 %)
(As of 06/23/2021 03:59 PM ET)
Add
Compare
Today's Range
$6.64
$6.98
50-Day Range
$5.96
$7.47
52-Week Range
$4.80
$10.67
Volume9,483 shs
Average Volume112,879 shs
Market Capitalization$176.82 million
P/E RatioN/A
Dividend YieldN/A
Beta0.09
30 days | 90 days | 365 days | Advanced Chart
Receive FENC News and Ratings via Email

Sign-up to receive the latest news and ratings for Fennec Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Fennec Pharmaceuticals logo

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.37 out of 5 stars

Medical Sector

770th out of 2,105 stocks

Biological Products, Except Diagnostic Industry

110th out of 198 stocks

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Fennec Pharmaceuticals (NASDAQ:FENC) Frequently Asked Questions

Is Fennec Pharmaceuticals a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Fennec Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Fennec Pharmaceuticals stock.
View analyst ratings for Fennec Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Fennec Pharmaceuticals?

Wall Street analysts have given Fennec Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Fennec Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Fennec Pharmaceuticals' next earnings date?

Fennec Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Fennec Pharmaceuticals
.

How were Fennec Pharmaceuticals' earnings last quarter?

Fennec Pharmaceuticals Inc (NASDAQ:FENC) issued its quarterly earnings results on Thursday, May, 13th. The company reported ($0.18) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.21) by $0.03.
View Fennec Pharmaceuticals' earnings history
.

How has Fennec Pharmaceuticals' stock price been impacted by Coronavirus?

Fennec Pharmaceuticals' stock was trading at $6.63 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, FENC stock has increased by 1.5% and is now trading at $6.73.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for FENC?

4 Wall Street analysts have issued 12 month price targets for Fennec Pharmaceuticals' stock. Their forecasts range from $11.00 to $17.00. On average, they expect Fennec Pharmaceuticals' stock price to reach $13.50 in the next year. This suggests a possible upside of 100.6% from the stock's current price.
View analysts' price targets for Fennec Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Fennec Pharmaceuticals' key executives?

Fennec Pharmaceuticals' management team includes the following people:
  • Mr. Rostislav Raykov, Pres, CEO & Director (Age 42)
  • Mr. Robert C. Andrade, Chief Financial Officer (Age 43)
  • Mr. Mark Gowland, Controller
  • Mr. Lei Fang, Pres of Pharstat Inc
  • Ms. Anne McKay, Regulatory Consultant (Age 64)

Who are some of Fennec Pharmaceuticals' key competitors?

What other stocks do shareholders of Fennec Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fennec Pharmaceuticals investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Pfizer (PFE), Amarin (AMRN), VBI Vaccines (VBIV), Gilead Sciences (GILD), Trevena (TRVN), Aldeyra Therapeutics (ALDX), Coherus BioSciences (CHRS) and Exelixis (EXEL).

What is Fennec Pharmaceuticals' stock symbol?

Fennec Pharmaceuticals trades on the NASDAQ under the ticker symbol "FENC."

Who are Fennec Pharmaceuticals' major shareholders?

Fennec Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (4.36%), Russell Investments Group Ltd. (0.76%), Northern Trust Corp (0.70%), Nuveen Asset Management LLC (0.39%), Morgan Stanley (0.16%) and UBS Group AG (0.16%).
View institutional ownership trends for Fennec Pharmaceuticals
.

Which major investors are selling Fennec Pharmaceuticals stock?

FENC stock was sold by a variety of institutional investors in the last quarter, including Northern Trust Corp, Russell Investments Group Ltd., Morgan Stanley, Hartford Financial Management Inc., Nuveen Asset Management LLC, Goldman Sachs Group Inc., and AQR Capital Management LLC.
View insider buying and selling activity for Fennec Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Fennec Pharmaceuticals stock?

FENC stock was purchased by a variety of institutional investors in the last quarter, including UBS Group AG, GSA Capital Partners LLP, BlackRock Inc., JPMorgan Chase & Co., Virtu Financial LLC, and Barclays PLC.
View insider buying and selling activity for Fennec Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Fennec Pharmaceuticals?

Shares of FENC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Fennec Pharmaceuticals' stock price today?

One share of FENC stock can currently be purchased for approximately $6.73.

How much money does Fennec Pharmaceuticals make?

Fennec Pharmaceuticals has a market capitalization of $175.00 million and generates $170,000.00 in revenue each year. The company earns $-18,110,000.00 in net income (profit) each year or ($0.76) on an earnings per share basis.

What is Fennec Pharmaceuticals' official website?

The official website for Fennec Pharmaceuticals is www.fennecpharma.com.

Where are Fennec Pharmaceuticals' headquarters?

Fennec Pharmaceuticals is headquartered at PO BOX 13628 68 TW ALEXANDER DRIVE, DURHAM NC, 27709.

How can I contact Fennec Pharmaceuticals?

Fennec Pharmaceuticals' mailing address is PO BOX 13628 68 TW ALEXANDER DRIVE, DURHAM NC, 27709. The company can be reached via phone at 919-636-4530.


This page was last updated on 6/23/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.